Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 320,858,368
  • Shares Outstanding, K 4,487,530
  • Annual Sales, $ 42,108 M
  • Annual Income, $ 14,643 M
  • EBIT $ 19,446 M
  • EBITDA $ 22,216 M
  • 60-Month Beta 0.65
  • Price/Sales 6.98
  • Price/Cash Flow 17.90
  • Price/Book 15.95

Options Overview Details

View History
  • Implied Volatility 50.76% ( -0.44%)
  • Historical Volatility 46.88%
  • IV Percentile 83%
  • IV Rank 57.52%
  • IV High 70.99% on 04/08/25
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 1.04
  • Today's Volume 38,601
  • Volume Avg (30-Day) 46,889
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 553,447
  • Open Int (30-Day) 533,544

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.88
  • Number of Estimates 4
  • High Estimate 0.92
  • Low Estimate 0.85
  • Prior Year 0.65
  • Growth Rate Est. (year over year) +35.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.13 +13.26%
on 05/16/25
71.57 -0.09%
on 05/30/25
+5.05 (+7.60%)
since 04/30/25
3-Month
57.00 +25.44%
on 04/21/25
91.90 -22.20%
on 03/05/25
-19.15 (-21.13%)
since 02/28/25
52-Week
57.00 +25.44%
on 04/21/25
148.15 -51.74%
on 06/25/24
-62.58 (-46.67%)
since 05/28/24

Most Recent Stories

More News
2 Top Stocks to Buy With Less Than $100

NVO : 71.50 (+2.94%)
LLY : 737.67 (+2.09%)
EXEL : 43.04 (+1.03%)
2 Beaten-Down Stocks to Buy on the Dip

NVO : 71.50 (+2.94%)
CAVA : 81.27 (-0.74%)
LLY : 737.67 (+2.09%)
AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip?

AbbVie ABBV stock has declined 12.6% in the past three months. The stock is also trading below its 50-day and 200-day moving averages. A lot of this price decline is related to the broader macroeconomic...

NVO : 71.50 (+2.94%)
LLY : 737.67 (+2.09%)
ABBV : 186.11 (+0.26%)
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer

Eli Lilly LLY recently announced that it has entered into a definitive agreement to acquire the privately held clinical-stage company SiteOne Therapeutics in a deal valued at $1 billion.Through this acquisition,...

NVO : 71.50 (+2.94%)
LLY : 737.67 (+2.09%)
VRTX : 442.05 (-1.13%)
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?

Eli Lilly LLY and AstraZeneca AZN are leading drugmakers with significant involvement in oncology, immunology, and the cardiometabolic disease space. Both are making substantial investments in next-generation...

AZN : 72.83 (+2.77%)
NVO : 71.50 (+2.94%)
LLY : 737.67 (+2.09%)
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.

NVO : 71.50 (+2.94%)
MS : 128.03 (-0.10%)
LLY : 737.67 (+2.09%)
3 Surprising Stocks That Have More Than Doubled in 2025

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted.

HIMS : 56.56 (+7.94%)
NVO : 71.50 (+2.94%)
GRPN : 29.13 (-1.09%)
FUBO : 3.66 (+1.10%)
DIS : 113.04 (+0.91%)
Why Novo Nordisk Stock Just Popped

President Trump has good news for Novo Nordisk investors, and more may be on the way.

NFLX : 1,207.23 (+1.89%)
NVDA : 135.13 (-2.92%)
NVO : 71.50 (+2.94%)
LLY : 737.67 (+2.09%)
"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy."

NFLX : 1,207.23 (+1.89%)
CVS : 64.04 (+2.01%)
GOOGL : 171.74 (-0.07%)
GOOG : 172.85 (-0.06%)
NVDA : 135.13 (-2.92%)
NVO : 71.50 (+2.94%)
CI : 316.64 (+1.47%)
MRK : 76.84 (+0.58%)
AMGN : 288.18 (+1.64%)
UNH : 301.91 (+1.25%)
AMZN : 205.01 (-0.34%)
WMT : 98.72 (+1.67%)
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More

This week, Novo Nordisk NVO announced the surprise resignation of its chief executive officer (CEO), Lars Fruergaard Jørgensen. Sanofi SNY announced the proposed acquisition of Vigil Neuroscience, a clinical-stage...

NVO : 71.50 (+2.94%)
MRK : 76.84 (+0.58%)
RHHBY : 40.3000 (+1.96%)
PFE : 23.49 (+0.17%)
SNY : 49.37 (-5.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 74.85
2nd Resistance Point 73.21
1st Resistance Point 72.35
Last Price 71.50
1st Support Level 69.86
2nd Support Level 68.22
3rd Support Level 67.36

See More

52-Week High 148.15
Fibonacci 61.8% 113.33
Fibonacci 50% 102.57
Fibonacci 38.2% 91.82
Last Price 71.50
52-Week Low 57.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar